Education and Training

Radiation Therapy Residency

Medical Students

Medical Physics Residency

A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis

The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of BMS-986278 in these participants.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • other: BMS-986278 Placebo
  • drug: BMS-986278

Eligibility


Inclusion Criteria:

For the idiopathic pulmonary fibrosis (IPF) Cohort

   - Diagnosis of IPF within 7 years of screening

   - Female and males ≥ 40 years of age

For the progressive fibrotic interstitial lung disease (PF-ILD) Cohort

   - Evidence of progressive ILD within the 24 months before screening

   - Female and male ≥ 21 years of age.

Exclusion Criteria:

   - Women of childbearing potential (WOCBP)

   - Active Smokers

   - Current malignancy or previous malignancy up to 5 years prior to screening

   - History of allergy to BMS-986278 or related compounds

Other protocol-defined inclusion/exclusion criteria apply

Ages Eligible for Study

21 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Rishi Raj, Site 0043
650-736-8083
Recruiting